Abstract
Over the past decade, treatment for obesity has been limited because of an incomplete understanding of the pathophysiology of obesity, lack of recognition of it as a disease, and limited efficacy of treatment options. Safety concerns related to medical and surgical approaches for obesity have also been a major barrier. The challenging nature of obesity management is reflected in a survey of primary care physicians which indicated that treating patients with obesity can be as difficult as treating patients with nicotine or alcohol dependence.
MeSH terms
-
Anti-Obesity Agents / therapeutic use*
-
Bupropion / therapeutic use
-
Dopamine Uptake Inhibitors / therapeutic use
-
Forecasting
-
Glucagon-Like Peptide 1 / analogs & derivatives
-
Glucagon-Like Peptide 1 / therapeutic use
-
Glucagon-Like Peptide-1 Receptor
-
Humans
-
Incretins / therapeutic use
-
Liraglutide
-
Naltrexone / therapeutic use
-
Narcotic Antagonists / therapeutic use
-
Obesity / prevention & control*
-
Receptors, Glucagon / agonists
Substances
-
Anti-Obesity Agents
-
Dopamine Uptake Inhibitors
-
GLP1R protein, human
-
Glucagon-Like Peptide-1 Receptor
-
Incretins
-
Narcotic Antagonists
-
Receptors, Glucagon
-
Bupropion
-
Naltrexone
-
Liraglutide
-
Glucagon-Like Peptide 1